The EMILIA trial assigned patients with HER2-positive advanced breast cancer, who had previously been treated with trastuzumab + taxane, to T-DM1 or lapatinib + capecitabine, and demonstrated that T-DM1 extended median PFS and OS for 3.2 and 6.8 months, with fewer side effects than lapatinib [78]. The gene discussed is ERBB2; the disease is breast carcinoma.